TO THE Consignee- Pharmaceutical Import Profile — Kenya (DGFT 2022–2026)

Name: TO THE Consignee- Pharmaceutical Import Records from India — 8 Products, $95.1K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

TO THE Consignee- — Pharmaceutical Importer Profile (2026) | 8 Products, $95.1K Trade | TransData Nexus

TO THE Consignee-

Pharmaceutical Importer · Kenya · Biologics & Immunotherapy Focus · $95.1K Total Trade · DGFT Verified

TO THE Consignee- is a pharmaceutical importer based in Kenya with a total trade value of $95.1K across 8 products in 4 therapeutic categories. Based on 46 verified import shipments from Indian Customs (DGFT) records, TO THE Consignee- is the #1 buyer in 1 product including Procarbazine. TO THE Consignee- sources from 3 verified Indian suppliers, with Zyphar's Pharmaceutics Private Limited accounting for 99.9% of imports.

TO THE Consignee- — Import Portfolio & Supplier Network

TO THE Consignee- import network — 8 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to TO THE Consignee-?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Zyphar's Pharmaceutics Private Limited	$6.4M	6,316	99.9%
Vea Impex (i) Private Limited	$3.0K	48	0.0%
San Marino Impex	$2.2K

What Formulations Does TO THE Consignee- Import?

Formulation	Value	Ships
Asper invoice no: zppl/xp/2223/405	$189.6K	4
Pharmaceutical products for human	$128.2K	171
As per invoice no:zppl/xp/2324/001	$109.0K	165
Asper invoice no: zppl/xp/2223/398	$101.1K	6
Asper invoice no: zppl/xp/2223/377	$90.5K	34
Asper invoice no: zppl/xp/2223/406	$90.5K	111
Asper invoice no: zppl/xp/2324/013	$82.1K	3
Asper invoice no: zppl/xp/2324/122	$68.2K	36
Asper invoice no: zppl/xp/2223/253	$54.0K	15
Asper invoice no: zppl/xp/2223/385	$53.0K	3
Asper invoice no: zppl/xp/2324/071	$52.6K	3
Asper invoice no: zppl/xp/2223/329	$50.0K	1
Asper invoice no: zppl/xp/2223/422	$50.0K	1
Asper invoice no: zppl/xp/2425/138 date:10/06/2024 sr no. 1 micafungin for injection USP 100MG	$50.0K	1
As per invoice no: zppl/xp/2425/559 date: 19.03.2025 sr no: 01 harmless pharmaceuticals product meant for human use	$42.1K	1

TO THE Consignee- imports 3,325 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 8 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ustekinumab	Biologics & Immunotherapy	$46.6K	2	3.7%	4
2	Mefloquine	Antimalarial & Antiparasitic	$18.0K	3	0.7%	10
3	Procarbazine	Advanced Oncology	$8.6K	7	3.3%	1
4	Adalimumab	Biologics & Immunotherapy	$7.8K	4	0.7%	9
5	Daunorubicin	Advanced Oncology	$6.4K	7	0.9%	9
6	Lomustine	Advanced Oncology	$4.3K	16	2.2%	4
7	Cabozantinib	Advanced Oncology	$2.0K	5	1.5%	7
8	Saxagliptin	Advanced Diabetes Medications	$1.5K	2	0.0%	13

TO THE Consignee- imports 8 pharmaceutical products across 4 categories into Kenya totaling $95.1K. The company is the #1 buyer for 1 product: Procarbazine.

TO THE Consignee- — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

TO THE Consignee- is a pharmaceutical importer and buyer based in Kenya, specializing in the acquisition of finished pharmaceutical formulations from international suppliers. The company plays a pivotal role in the Kenyan pharmaceutical distribution network, ensuring the availability of a diverse range of medications to meet the country's healthcare needs. While specific details about its headquarters and parent company are not publicly disclosed, TO THE Consignee- is recognized for its significant contributions to the importation and distribution of pharmaceutical products within Kenya.

2Distribution Network

TO THE Consignee- operates a comprehensive distribution network across Kenya, facilitating the efficient delivery of pharmaceutical products to various healthcare providers, including hospitals, clinics, and pharmacies. The company's logistics capabilities are designed to ensure timely and reliable supply chains, adhering to the stringent standards set by the Pharmacy and Poisons Board (PPB) of Kenya. This network is integral to maintaining the availability of essential medicines throughout the country.

3Industry Role

In Kenya's pharmaceutical supply chain, TO THE Consignee- functions primarily as a wholesaler and importer. By sourcing finished pharmaceutical formulations from international suppliers, the company bridges the gap between global manufacturers and the Kenyan market, ensuring that a wide array of medications is accessible to meet the diverse healthcare needs of the population.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — TO THE Consignee-

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

TO THE Consignee- demonstrates a high degree of sourcing concentration, with its top five imported products accounting for 91.9% of its total import value. This concentration indicates a strategic focus on specific high-demand medications, which can lead to cost efficiencies and streamlined operations. However, such dependency also poses risks, including potential supply chain disruptions if any of these key products face shortages or regulatory challenges. The company's reliance on a limited number of suppliers for these products suggests a need for robust contingency planning to mitigate potential risks associated with supplier dependency.

2Supply Chain Resilience

The resilience of TO THE Consignee-'s supply chain is closely tied to its sourcing strategy. The company's concentration on a select group of products and suppliers may limit its ability to adapt quickly to changes in the global pharmaceutical market. To enhance supply chain resilience, it would be prudent for TO THE Consignee- to diversify its supplier base and consider alternative sourcing options. Additionally, ensuring compliance with the PPB's regulations and maintaining strong relationships with suppliers can further strengthen the supply chain's robustness.

Strategic Implications

Importing Pharmaceuticals into Kenya — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Kenya

1Regulatory Authority & Framework

In Kenya, the Pharmacy and Poisons Board (PPB) serves as the primary regulatory authority overseeing the importation, distribution, and sale of pharmaceutical products. The PPB is responsible for ensuring that all pharmaceutical products meet the required standards of quality, safety, and efficacy before they are permitted for use in the country. Key legislation governing pharmaceutical imports includes the Pharmacy and Poisons Act, which outlines the procedures for drug registration, importation, and distribution. Additionally, the Pharmacy and Poisons (Registration of Health Products and Technologies) Rules provide detailed guidelines on the registration process for health products, including pharmaceuticals. These regulations are designed to protect public health by ensuring that only safe and effective medicines are available in the Kenyan market.

2Import Licensing & GMP

Importers of pharmaceutical products into Kenya are required to obtain an import license from the PPB. This license is issued upon the successful registration of the pharmaceutical product, which involves submitting a sample for evaluation and obtaining a certificate of analysis from a recognized laboratory. The PPB also mandates that imported pharmaceutical products comply with Good Manufacturing Practice (GMP) standards. While the PPB does not specify which GMP certifications are acceptable, it is generally understood that certifications from reputable authorities such as the World Health Organization (WHO) are recognized. Additionally, importers must possess a wholesale dealer's license, which is issued to registered pharmacists and is subject to annual renewal.

TO THE Consignee- — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

TO THE Consignee- focuses on importing pharmaceutical products across four therapeutic categories, with a significant emphasis on Biologics & Immunotherapy (57.2%), Advanced Oncology (22.4%), and Antimalarial & Antiparasitic (18.9%). This strategic focus aligns with the pressing healthcare needs in Kenya, where there is a high demand for treatments in these areas. The company's importation of specific products such as Ustekinumab, Mefloquine, and Procarbazine indicates a targeted approach to addressing prevalent health conditions in the country.

2Sourcing Profile

TO THE Consignee- primarily sources generic pharmaceutical products from India, focusing on finished formulations rather than active pharmaceutical ingredients (APIs) or bulk drugs. This sourcing strategy allows the company to offer a wide range of medications that are both cost-effective and readily available. India's well-established pharmaceutical manufacturing industry, known for its adherence to international quality standards, makes it a reliable source for these products.

3Market Positioning

Based on its product mix, TO THE Consignee- serves a broad segment of the Kenyan pharmaceutical market, including retail pharmacies, hospitals, and government tenders. The company's focus on high-demand therapeutic areas positions it as a key supplier of essential medicines, catering to the diverse healthcare needs of the Kenyan population.

Seller's Guide — How to Become a Supplier to TO THE Consignee-

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to partner with TO THE Consignee- by offering products that align with the company's import profile, particularly in the therapeutic areas of Biologics & Immunotherapy, Advanced Oncology, and Antimalarial & Antiparasitic treatments. By understanding the specific products and formulations that TO THE Consignee- imports, Indian exporters can tailor their offerings to meet the company's needs, potentially gaining access to the Kenyan market.

2Requirements & Qualifications

Indian exporters seeking to supply TO THE Consignee- and the Kenyan market must ensure that their products are registered with the PPB and comply with the regulatory requirements set forth by the board. This includes obtaining the necessary import licenses, adhering to GMP standards recognized by the PPB, and ensuring that products meet the labeling and packaging requirements specified by the board.

3How to Approach

Frequently Asked Questions — TO THE Consignee-

What products does TO THE Consignee- import from India?

TO THE Consignee- imports 8 pharmaceutical products across 4 categories. Top imports: Ustekinumab ($46.6K), Mefloquine ($18.0K), Procarbazine ($8.6K), Adalimumab ($7.8K), Daunorubicin ($6.4K).

Who supplies pharmaceuticals to TO THE Consignee- from India?

TO THE Consignee- sources from 3 verified Indian suppliers. The primary supplier is Zyphar's Pharmaceutics Private Limited (99.9% of imports, $6.4M).

What is TO THE Consignee-'s total pharmaceutical import value?

TO THE Consignee-'s total pharmaceutical import value from India is $95.1K, based on 46 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does TO THE Consignee- focus on?

TO THE Consignee- imports across 4 categories. The largest: Biologics & Immunotherapy (57.2%), Advanced Oncology (22.4%), Antimalarial & Antiparasitic (18.9%).

Get Full TO THE Consignee- Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.